The European Medicines Agency is Studying Lemtrada's Side Effects

Lemtrada Stroke Lawsuit News

Lemtrada can cause immediate damage to the blood vessels leading to the heart and brain resulting in a paralyzing stroke or sudden death from a heart attack

Tuesday, July 30, 2019 - A hard-hitting article in Multiple Sclerosis News Today has brought to light the potentially life-threatening adverse side effects being caused by anti-multiple sclerosis treatment Lemtrada. Reports of serious side effects have prompted the European Medicines Agency (EMA), known as the European Agency for the Evaluation of Medicinal Products prior to 2004, to initiate a review of alemtuzumab, known by its brand name Lemtrada. The EMA evaluates and supervises medicinal products in the European Union. The Agency has received adverse event reports including instant, spontaneous death that has prompted them to restrict the use of the drug on the continent until more is known. According to, "the EMA has started a review of the multiple sclerosis medicine Lemtrada (alemtuzumab) following new reports of immune-mediated conditions (caused by the body's defence system not working properly) and problems with the heart and blood vessels with the medicine, including fatal cases." Only adult RRMS patients that have tried two or more alternative treatments without success are now permitted to begin Lemtrada treatments. Lemtrada lawyers specialize in representing people and their loved ones harmed and affected by the aftereffects of major drug recalls and offer a free consultation.

Lemtrada is given as a drug of last resort to patients suffering from relapsing-remitting multiple sclerosis (RRMS), a condition affecting the majority of multiple sclerosis sufferers. RRMS is characterized by the patient suffering from noticeable spasticity, or otherwise being unable to control the movement of their body parts including bowel movement and brain functions like memory. RRMS also adversely effects the speech and eyesight. RRMS attacks happen at intervals and last for a period of time followed by recovery. Without treatment, the seizures (for lack of a better term) may increase in severity and duration until they eventually become continuous. There is no guarantee that the seizures will worsen and stay the same for some people. In between seizures a patient is said to be in remission and can lead a relatively normal life.

RRMS is a disease that attacks the myelin nerve sheathing and causes the nerves to fire off false signals to the muscles, to put it simply. This causes brain and spinal cord lesions which serve as an early indication that the person may have MS. "Women in their 20's are three times more likely to be affected by RRMS."

Lemtrada is extremely effective at lengthening the remission time RRMS patient enjoy but the drug has terrible side effects that threaten a patient's life. Lemtrada is administered once per year via an IV drip and patients have actually suffered paralyzing strokes within 24 hours of receiving Lemtrada (alemtuzumab).

The EMA also recommends that physicians make their RRMS patients plainly aware of Lemtrada's life-threatening side effects so that the patient may make an informed decision. Those warnings include that Lemtrada (alemtuzumab) causes liver damage, damage to the blood vessels leading to and from the heart, and most importantly "bleeding in the lungs, heart attack, stroke, cervicocephalic arterial dissection (tears in the lining of the arteries in the head and neck)."

More Recent Lemtrada Stroke Lawsuit News:

No-Cost, No-Obligation Lemtrada Lawsuit Case Review If You or a Loved One Suffered from Lemtrada Stroke Complications

OnderLaw, LLC is a St. Louis personal injury law firm handling serious injury and death claims across the country. Its mission is the pursuit of justice, no matter how complex the case or strenuous the effort. The Onder Law Firm has represented clients throughout the United States in pharmaceutical and medical device litigation such as Pradaxa, Lexapro and Yasmin/Yaz, where the firm's attorneys held significant leadership roles in the litigation, as well as Actos, DePuy, Risperdal and others. The Onder Law Firm has won more than $300 million in four talcum powder ovarian cancer lawsuits in St. Louis. Law firms throughout the nation often seek its experience and expertise on complex litigation.